EZH2 and cancer: Remarkably, within six-month in 2020, the FDA granted two approvals for Tazemetostat, an EZH2 inhibitor, heralding a groundbreaking new chapter in the field of epigenetic therapeutics for oncology.771 The utilization of epigenetic drugs in cancer therapy primarily focuses on the inhibition of aberrant DNA methylation, histone methylation, and histone acetylation.665 To date, several drugs targeting specific epigenetic mechanisms have been approved by FDA.